PEG-detachable cationic polyaspartamide derivatives bearing stearoyl moieties for systemic siRNA delivery toward subcutaneous Bxpc3 pancreatic tumor

Journal of Drug Targeting

Volumn 20, Issue 1, 2012, Pages 33-42

  Kim, Hyun Jin ^a   Oba, Makoto ^b   Pittella, Frederico ^a   Nomoto, Takahiro ^a   Cabral, Horacio ^a   Matsumoto, Yu ^b   Miyata, Kanjiro ^b   Nishiyama, Nobuhiro ^b   Kataoka, Kazunori ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antiangiogenesis; Polyaspartamide; SiRNA delivery; Stearoylation

Indexed keywords

CATIONIC POLYASPARTAMIDE DERIVATIVE; DISULFIDE; MACROGOL; POLY(ETHYLENE GLYCOL)DISULFIDE POLY(N[N (2 AMINOETHYL) 2 AMINOETHYL]ASPARTAMIDE); POLYCATION; POLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CANCER CELL; CANCER INHIBITION; CIRCULATION; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; ENDOSOME; FEMALE; GENE SILENCING; HYDROPHOBICITY; LONGEVITY; MOUSE; NONHUMAN; PANCREAS TUMOR; PKA; PRIORITY JOURNAL; RNA TRANSPORT;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PEPTIDES; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; RNA, SMALL INTERFERING; STEARIC ACIDS; SUBCUTANEOUS TISSUE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83155191792     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.632010     Document Type: Article

References (29)

1. Aagaard L, Rossi JJ. (2007). RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev, 59, 75-86. (Pubitemid 46770900)
2. Dykxhoorn DM. (2009). RNA interference as an anticancer therapy: a patent perspective. Expert Opin Ther Pat, 19, 475-491.
3. He S, Zhang D, Cheng F, Gong F, Guo Y. (2009). Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol Biol Rep, 36, 2153-2163.
4. Christie RJ, Nishiyama N, Kataoka K. (2010). Delivering the code: polyplex carriers for deoxyribonucleic acid and ribonucleic acid interference therapies. Endocrinology, 151, 466-473.
5. Fang J, Nakamura H, Maeda H. (2011). The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev, 63, 136-151.
6. Whitehead KA, Langer R, Anderson DG. (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov, 8, 129-138.
7. Ishii A, Miyata K, Lee Y, Wu S, Oba M, Nishiyama N, Kataoka K. (2010). Introduction of stearoyl moieties into a biocompatible cationic polyaspartamide derivative, PAsp(DET), with endosomal escaping function for enhanced siRNA-mediated gene knockdown. J Control Release, 145, 141-148.
8. Miyata K, Oba M, Nakanishi M, Fukushima S, Yamasaki Y, Koyama H, Nishiyama N, Kataoka K. (2008). Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective, endosomal membrane destabilization with amplified transfection and negligible cytotoxicity. J Am Chem Soc, 130, 16287-16294.
9. Owens DE 3rd, Peppas NA. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm, 307, 93-102. (Pubitemid 41773257)
10. Nomoto T, Matsumoto Y, Miyata K, Oba M, Fukushima S, Nishiyama N, Yamasoba T, Kataoka K. (2011). In situ quantitative monitoring of polyplexes and polyplex micelles in the blood circulation using intravital real-time confocal laser scanning microscopy. J Control Release, 151, 104-109.
11. Itaka K, Kataoka K. (2009). Recent development of nonviral gene delivery systems with virus-like structures and mechanisms. Eur J Pharm Biopharm, 71, 475-483.
12. Lee Y, Kataoka K. (2009). Biosignal-sensitive polyion complex micelles for the delivery of biopharmaceuticals. Soft Matter, 5, 3810-3817.
13. Soundara Manickam D, Oupický D. (2006). Polyplex gene delivery modulated by redox potential gradients. J Drug Target, 14, 519-526. (Pubitemid 44592885)
14. Park K, Lee MY, Kim KS, Hahn SK. (2010). Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneiminehyaluronic acid conjugate. Biomaterials, 31, 5258-5265.
15. Matsumoto S, Christie RJ, Nishiyama N, Miyata K, Ishii A, Oba M, Koyama H, Yamasaki Y, Kataoka K. (2009). Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery. Biomacromolecules, 10, 119-127.
16. Takae S, Miyata K, Oba M, Ishii T, Nishiyama N, Itaka K, Yamasaki Y, Koyama H, Kataoka K. (2008). PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J Am Chem Soc, 130, 6001-6009. (Pubitemid 351620847)
17. Jones DP, Carlson JL, Mody VC, Cai J, Lynn MJ, Sternberg P. (2000). Redox state of glutathione in human plasma. Free Radic Biol Med, 28, 625-635. (Pubitemid 30136044)
18. Morré DJ, Morré DM. (2003). Cell surface NADH oxidases (ECTONOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases. Free Radic Res, 37, 795-808. (Pubitemid 36939596)
19. Balendiran GK, Dabur R, Fraser D. (2004). The role of glutathione in cancer. Cell Biochem Funct, 22, 343-352. (Pubitemid 39518098)
20. Holmes K, Roberts OL, Thomas AM, Cross MJ. (2007). Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal, 19, 2003-2012. (Pubitemid 47354167)
21. Li SD, Chono S, Huang L. (2008). Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther, 16, 942-946. (Pubitemid 351587105)
22. Akagi D, Oba M, Koyama H, Nishiyama N, Fukushima S, Miyata T, Nagawa H, Kataoka K. (2007). Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene Ther, 14, 1029-1038. (Pubitemid 46965272)
23. AL-Badri ZM, Som A, Lyon S, Nelson CF, Nüsslein K, Tew GN. (2008). Investigating the effect of increasing charge density on the hemolytic activity of synthetic antimicrobial polymers. Biomacromolecules, 9, 2805-2810.
24. Matsumoto Y, Nomoto T, Cabral H, Matsumoto Y, Watanabe S, Christie RJ, Miyata K, Oba M, Ogura T, Yamasaki Y, Nishiyama N, Yamasoba T, Kataoka K. (2010). Direct and instantaneous observation of intravenously injected substances using intravital confocal micro-videography. Biomed Opt Express, 1, 1209-1216.
25. Navarro J, Obrador E, Carretero J, Petschen I, Avinó J,Perez P, Estrela JM. (1999). Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radic Biol Med, 26, 410-418.
26. Sun W, Davis PB. (2010). Reducible DNA nanoparticles enhance in vitro gene transfer via an extracellular mechanism. J Control Release, 146, 118-127.
27. Meng F, Hennink WE, Zhong Z. (2009). Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials, 30, 2180-2198.
28. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. (2008). Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release, 129, 107-116.
29. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res, 32, e149.